0000880771-15-000040.txt : 20150318
0000880771-15-000040.hdr.sgml : 20150318
20150318170837
ACCESSION NUMBER: 0000880771-15-000040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150316
FILED AS OF DATE: 20150318
DATE AS OF CHANGE: 20150318
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun
CENTRAL INDEX KEY: 0001291656
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 15710770
MAIL ADDRESS:
STREET 1: SCICLONE PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
rivet-form4.xml
PRIMARY DOCUMENT
X0306
4
2015-03-16
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001291656
Cheung Wilson Wai-Shun
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
0
1
0
0
CFO & Senior VP, Finance
Stock Option (right to buy)
8.83
2015-03-16
4
A
0
84000
0
A
2025-03-16
Common Stock
84000
84000
D
Restricted Stock Unit
2015-03-16
4
A
0
12000
0
A
Common Stock
12000
49500
D
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of such shares vest from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
/s/Friedhelm Blobel, Attorney-in-Fact for: Wilson W. Cheung
2015-03-18